APIMEDS PHARMACEUTICALS US INC (APUS)
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
$2.42-3.59%
Close 2026-09-04 · 1-day change
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APUS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of — · Company calendar date is not available
APUS — officer change
Dated 2026-05-04
Director — Jakap Koo: Mr. Koo's resignation or removal is part of a significant corporate settlement and restructuring.
Why it matters: Filing the Form 10-K is crucial to avoid delisting from the NYSE. It shows the company's commitment to compliance.
Supportive ifThe Form 10-K is filed with the SEC by April 30, 2026.
Worry ifThe Form 10-K is not filed by April 30, 2026, leading to potential delisting.
Why it matters: Completing strategic partnerships is key for growth and market expansion. Progress here can signal future revenue.
Supportive ifThe company announces a new strategic partnership that supports its growth plans.
Worry ifNo new partnerships were announced. This shows growth efforts are not moving forward.
Why it matters: Partnerships help growth and entry into new markets, like Korean cosmetics.
Supportive ifA new partnership with a Korean company has been announced.
Worry ifNo new partnerships announced within the next quarter.
Why it matters: Fixing this issue is key for keeping the listing and investor trust.
Worry ifSuccessful appeal or meeting NYSE rules to avoid being delisted.
Less concerning ifFailure to resolve delisting notice by the next earnings call.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$406 on $10,000 · ±4.1% | How much price usually moves either way. |
| Bad day | $1,523 loss on $10,000 · 15.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,379 loss on $10,000 · 93.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Success in this area could drive growth and improve company outlook.
Supportive ifLook for a new partnership or product launch in Korean cosmetics.
Worry ifNo new developments or partnerships in Korean cosmetics by the next earnings call.
Why it matters: Compliance with NYSE standards is critical. Updates will indicate if the company avoids delisting.
Worry ifThe NYSE confirms that the company remains compliant and avoids delisting.
Less concerning ifThe NYSE says it will suspend or remove the company from the exchange.
Why it matters: The new CEO could change company direction. This may affect growth and compliance efforts.
Watch forThe company sees good changes in strategy or performance with the new CEO.
Also watch forThe company still has problems with compliance and growth after the CEO change.
Why it matters: Finishing partnerships can help the company. It can also create more money opportunities.
Supportive ifLook for news about a finished partnership with a big company.
Worry ifNo partnerships finished or big delays reported by the next earnings call.
Why it matters: New partnerships could enhance growth and market reach for APIMEDS.
Supportive ifA new partnership was announced. It fits APIMEDS' goals for growth.
Worry ifNo new partnerships were announced in the next quarter. This shows growth efforts are slow.
Why it matters: Management needs to respond to the delisting notice. This impacts investor trust and stock stability.
Supportive ifManagement says they made good progress on the NYSE delisting notice.
Worry ifManagement says there is no progress on the NYSE delisting notice.
Why it matters: The NYSE's choice will decide if the company stays listed. This impacts investor trust.
Worry ifThe NYSE confirms that Apimeds has regained compliance with listing standards.
Less concerning ifThe NYSE starts suspension or delisting steps because of ongoing non-compliance.